Is Emergent Biosolutions Inc (EBS) overvalued? · rev $1.04B
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
This page asks whether Emergent Biosolutions Inc (EBS) looks expensive on cached numbers — not a short thesis.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
EBS currently screens at market cap $416.4M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EBS 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EBS stock page for the full model, not this heading.
Not investment advice.